Xcenda Research Highlighted at 59th ASH Annual Meeting & Expo

November 30, 2017

Xcenda is proud to present research and findings at the upcoming 59th ASH Annual Meeting & Exposition in Atlanta, GA on December 9-12, 2017.

 

Xcenda oncology and hematology experts will present the following posters:

 

Abstract Title Xcenda Author(s) Date | Time | Location Abstract/Poster No. 
Treatment Characteristics and Outcomes for Newly Diagnosed Elderly Patients with Acute Myeloid Leukemia (AML) Treated in the United States with Either 7+3 or a Hypomethylating Agent (HMA) 
Eileen Farrelly, MPH; Sharanya Murty, PhD; Augustina Ogbonnaya, MPH; Michael T. Eaddy, PharmD, PhD
 
Saturday, December 9, 2017, 5:30 PM-7:30 PM
Bldg A, Lvl 1, Hall A2 2167 / Session: 904. Outcomes Research—Malignant Conditions: Poster I 
Healthcare Costs in Elderly Patients with Acute Myeloid Leukemia (AML) in Routine Clinical Care in the United States (US) 
Sharanya Murty, PhD; Megan Pollack, PharmD; Augustina Ogbonnaya, MPH; Michael T. Eaddy, PharmD, PhD
 
Saturday, December 9, 2017, 5:30 PM-7:30 PM
Bldg A, Lvl 1, Hall A2 3459 / Session: 904. Outcomes Research—Malignant Conditions: Poster II 
Evaluation of Treatment Patterns Among Patients with Newly Diagnosed, Persistent, and Chronic Immune Thrombocytopenia (ITP) Treated with Eltrombopag in Real World Setting in the US 
Dana Stafkey-Mailey, PharmD, PhD; Tasneem Lokhandwala, BPharm, MS, PhD; Jing Yuan; Pamela Landsman-Blumberg, MPH DrPH
 
Saturday, December 9, 2017, 5:30 PM-7:30 PM
Bldg A, Lvl 1, Hall A2 2078 / Session: 901. Health Services Research—Non-Malignant Conditions: Poster I 
Duration of Therapy (DOT) and Time to Next Therapy (TTNT) of Bortezomib, Carfilzomib and Ixazomib Combinations with Lenalidomide/Dexamethasone (VRd, KRd, IRd) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Clinical Practice in the United States Vs Clinical Trial Experience 
Aditya Raju, MS; Eileen Farrelly, MPH; Marlo Blazer, PharmD
 
Saturday, December 9, 2017, 5:30 PM-7:30 PM
Bldg A, Lvl 1, Hall A2 1818 / Session: 653. Myeloma: Therapy, excluding Transplantation: Poster I 
Survival Outcomes after First-Line Therapy in Follicular Lymphoma Patients Treated with Bendamustine 
Laurie Hamilton, MS; Augustina Ogbonnaya, MPH; Kristin Hennenfent, PharmD
 
Saturday, December 9, 2017, 5:30 PM-7:30 PM
 2184 / Session: 904. Outcomes Research—Malignant Conditions: Poster I 
Treatment Patterns in Newly Treated and Relapse/Refractory Patients with Follicular Lymphoma in Routine Clinical Care – a United States Electronic Medical Record Database Study 
Laurie Hamilton, MS; Augustina Ogbonnaya, MPH; Kristin Hennenfent, PharmD; Michael T. Eaddy, PharmD, PhD
 
Monday, December 11, 2017, 6:00 PM-8:00 PM
Bldg A, Lvl 1, Hall A2 4059 / Session: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Poster III 
Economic Impact and Healthcare Utilization in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) in Routine Clinical Care in the United States (US) – a Claims Database Study 
Laurie Hamilton, MS; Augustina Ogbonnaya, MPH; Kristin Hennenfent, PharmD; Michael T. Eaddy, PharmD, PhD
 
Saturday, December 9, 2017, 5:30 PM-7:30 PM
Bldg A, Lvl 1, Hall A2 2185 / Session: 904. Outcomes Research—Malignant Conditions: Poster I 
Healthcare Burden of Patients with Follicular Lymphoma (FL) in Routine Clinical Care in the United States 
Laurie Hamilton, MS; Augustina Ogbonnaya, MPH; Kristin Hennenfent, PharmD; Michael T. Eaddy, PharmD, PhD
 
Saturday, December 9, 2017, 5:30 PM-7:30 PM
Bldg A, Lvl 1, Hall A2 2183 / Session: 904. Outcomes Research—Malignant Conditions: Poster I 
US Economic Impact of Recombinant FVIII Vs Plasma-Derived FVIII/VWF in Previously Untreated Hemophilia a Patients 
Ken O'Day;
Kellie Meyer
 
Saturday, December 9, 2017, 5:30 PM-7:30 PM
Bldg A, Lvl 1, Hall A2 2088 / Session: 901. Health Services Research—Non-Malignant Conditions: Poster I